Chengdu Kanghong Pharmaceutical Group Co.,Ltd.
As of 17 November 2026, for the company name Chengdu Kanghong Pharmaceutical Group Co.,Ltd. as recorded, 2 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 61 records, across 28 drug names; since 21 August 2026, the records list Marketing application approved: 1 application; the chemical-drug catalogue lists 21 active records with this name as holder.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/17.
Drug filings
61 acceptance records as first applicant, grouped into 28 source drug names. Source data as of 2026/11/17.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Vortioxetine Hydrobromide Tablets 1 records · Latest accepted 2026/02/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2600358 | Supplement | 2026/02/14 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
KHN707片 · No verified English name 2 records · Latest accepted 2025/12/16
New drug · 2
Vonoprazan Fumarate Tablets 4 records · Latest accepted 2025/10/21
Supplement · 2Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2502146 | Supplement | 2025/10/21 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHB2502145 | Supplement | 2025/10/21 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHS2201711 | Generic | 2022/10/12 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHS2201710 | Generic | 2022/10/12 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Apalutamide Tablets 1 records · Latest accepted 2025/08/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2503102 | Generic | 2025/08/23 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
Amisulpride Oral Solution 1 records · Latest accepted 2025/08/01
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2502767 | Generic | 2025/08/01 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Tai Ji Group Sichuan Tai Ji Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Ibrutinib Capsules 1 records · Latest accepted 2025/06/27
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2502292 | Generic | 2025/06/27 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Sodium Hyaluronate Eye Drops 4 records · Latest accepted 2025/04/08
Supplement · 3Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2500697 | Supplement | 2025/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Ningxia Kang Ya Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2500696 | Supplement | 2025/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Ningxia Kang Ya Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2500695 | Supplement | 2025/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Ningxia Kang Ya Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2301831 | Generic | 2023/07/07 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Ningxia Kang Ya Pharma Co., Ltd. romanized | CDE ↗ |
KH607片 · No verified English name 5 records · Latest accepted 2025/02/28
New drug · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2500224 | New drug | 2025/02/28 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2500223 | New drug | 2025/02/28 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2300513 | New drug | 2023/05/12 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2300512 | New drug | 2023/05/12 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2300511 | New drug | 2023/05/12 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Perampanel Tablets 2 records · Latest accepted 2025/02/08
Generic · 2
KHN702片 · No verified English name 3 records · Latest accepted 2025/01/11
New drug · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2500057 | New drug | 2025/01/11 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2500056 | New drug | 2025/01/11 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2500055 | New drug | 2025/01/11 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Brexpiprazole Orally Disintegrating Tablets 3 records · Latest accepted 2024/09/07
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402954 | Generic | 2024/09/07 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHS2402952 | Generic | 2024/09/07 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHS2402951 | Generic | 2024/09/07 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
KH629片 · No verified English name 6 records · Latest accepted 2024/08/09
New drug · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2400799 | New drug | 2024/08/09 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2400798 | New drug | 2024/08/09 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2400797 | New drug | 2024/08/09 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2301036 | New drug | 2023/09/26 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2301035 | New drug | 2023/09/26 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2301034 | New drug | 2023/09/26 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Brexpiprazole Tablets 2 records · Latest accepted 2024/07/30
Generic · 2
Mirabegron Extended-release Tablets 1 records · Latest accepted 2024/06/25
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401877 | Generic | 2024/06/25 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Epalrestat Tablets 1 records · Latest accepted 2024/04/17
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2401145 | Generic | 2024/04/17 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Tofacitinib Citrate Extended Release tablets 1 records · Latest accepted 2023/09/27
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302608 | Generic | 2023/09/27 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
立他司特滴眼液 · No verified English name 2 records · Latest accepted 2023/09/11
Generic · 2
Quetiapine Fumarate Tablets 3 records · Latest accepted 2023/09/02
Generic · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2302363 | Generic | 2023/09/02 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHS2302362 | Generic | 2023/09/02 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHS2302361 | Generic | 2023/09/02 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Aripiprazole Orally Disintegrating tablets 1 records · Latest accepted 2023/08/21
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2301855 | Supplement | 2023/08/21 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Venlafaxine Hydrochloride Extended Release Tablets 2 records · Latest accepted 2023/04/15
Supplement · 2
Pranoprofen Eye Drops 1 records · Latest accepted 2023/03/27
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2300905 | Generic | 2023/03/27 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | CDE ↗ |
Pimavanserin Tartrate Capsules 1 records · Latest accepted 2022/08/22
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHL2200072 | Generic | 2022/08/22 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Escitalopram Oxalate Tablets 2 records · Latest accepted 2022/07/07
Generic · 2
Cariprazine hydrochloride Capsules 4 records · Latest accepted 2022/04/08
Generic · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHL2200031 | Generic | 2022/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHL2200030 | Generic | 2022/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHL2200029 | Generic | 2022/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CYHL2200028 | Generic | 2022/04/08 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Obeticholic Acid Tablets 2 records · Latest accepted 2022/02/10
Generic · 2
草酸艾司西酞普兰口服溶液 · No verified English name 1 records · Latest accepted 2021/08/16
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2101584 | Generic | 2021/08/16 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Chengdu Di Kang Pharma Co., Ltd. romanized | CDE ↗ |
KH737滴眼液 · No verified English name 3 records · Latest accepted 2021/08/03
New drug · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CXHL2101366 | New drug | 2021/08/03 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2101365 | New drug | 2021/08/03 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
| CXHL2101364 | New drug | 2021/08/03 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | CDE ↗ |
Aripiprazole Oral Solution 1 records · Latest accepted 2021/03/12
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2100298 | Supplement | 2021/03/12 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Guo Yao Group Yi Bin Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Changes in the last 90 days
1 events from 2026/08/21 to 2026/11/18. CDE data as of 2026/11/17; NMPA data as of 2026/11/17.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Marketing application approved: 1 application
- 2026/11/03Marketing application approved
Ibrutinib Capsules
CYHS2502292 · 国药准字H20266472
Fact date: 2026/11/03 · Publication date: 2026/11/05 · Date added to this site: 2026/11/06
View source · Table row 86 ↗
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/17.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Apalutamide Tablets | CYHS2503102 | Generic | 2025/08/23 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
| Amisulpride Oral Solution | CYHS2502767 | Generic | 2025/08/01 | Chengdu Kanghong Pharmaceutical Group Co.,Ltd.; Tai Ji Group Sichuan Tai Ji Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
21 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/17. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Perampanel Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20264399 | 2026/05/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Perampanel Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20264400 | 2026/05/19 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Brexpiprazole Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20256389 | 2025/12/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Brexpiprazole Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20256388 | 2025/12/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Mirabegron Extended-release Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20255960 | 2025/11/18 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Epalrestat Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20255572 | 2025/09/23 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Tofacitinib Citrate Extended Release tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20249436 | 2024/11/22 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Quetiapine Fumarate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20249365 | 2024/11/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Quetiapine Fumarate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20249364 | 2024/11/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Quetiapine Fumarate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20249366 | 2024/11/15 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Escitalopram Oxalate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20234593 | 2023/12/05 | Not stated by source | CDE ↗ |
| Escitalopram Oxalate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20234592 | 2023/12/05 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vortioxetine Hydrobromide Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20213844 | 2021/11/03 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Pramipexole Dihydrochloride Prolonged-release Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20213672 | 2021/08/25 | Not stated by source | CDE ↗ |
| Pramipexole Dihydrochloride Prolonged-release Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20213673 | 2021/08/25 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Mosapride Citrate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H19990313 | 2020/12/09 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Venlafaxine Hydrochloride Extended Release Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20070269 | 2019/10/23 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Aripiprazole Orally Disintegrating tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20060521 | 2018/12/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Aripiprazole Orally Disintegrating tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20060522 | 2018/12/18 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Vonoprazan Fumarate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20244425 | 2024/07/09 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Vonoprazan Fumarate Tablets | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | Chengdu Kanghong Pharmaceutical Group Co.,Ltd. | 国药准字H20244426 | 2024/07/09 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/17.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/17.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/17
- Chemical-drug catalogue
- Last successful update: 2026/11/17
- API registrations
- Last successful update: 2026/11/17
- NMPA drug delivery notices
- Last successful update: 2026/11/17
Loaded notices dated 2026-11-03 to 2026-11-17; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.